Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research report issued to clients and investors on Friday. They presently have a $239.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target points to a potential upside of 55.69% from the stock’s previous close.

ICPT has been the subject of several other reports. Wells Fargo & Co. restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 28th. Cantor Fitzgerald started coverage on Intercept Pharmaceuticals in a research note on Wednesday, July 6th. They issued a “sell” rating and a $58.00 price objective for the company. Robert W. Baird restated an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Thursday, September 22nd. Morgan Stanley restated a “sell” rating and issued a $80.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, August 5th. Finally, Oppenheimer Holdings Inc. reduced their price objective on Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, August 5th. Five research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $177.67.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.039% during midday trading on Friday, reaching $155.105. The company’s stock had a trading volume of 163,574 shares. The firm has a 50 day moving average price of $158.07 and a 200 day moving average price of $150.46. The firm’s market cap is $3.84 billion. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $217.99.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, topping the consensus estimate of ($3.69) by $0.55. The firm earned $5.52 million during the quarter, compared to analyst estimates of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. Intercept Pharmaceuticals’s revenue was up 1140.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.99) EPS. Equities research analysts forecast that Intercept Pharmaceuticals will post ($16.31) EPS for the current fiscal year.

In related news, CMO David Shapiro sold 3,545 shares of the stock in a transaction dated Monday, September 26th. The shares were sold at an average price of $165.08, for a total value of $585,208.60. Following the sale, the chief marketing officer now directly owns 45,732 shares of the company’s stock, valued at approximately $7,549,438.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lisa Bright sold 246 shares of the stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00. Following the completion of the sale, the insider now directly owns 18,460 shares in the company, valued at $2,935,140. The disclosure for this sale can be found here. Insiders own 9.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado raised its stake in Intercept Pharmaceuticals by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,075 shares of the biopharmaceutical company’s stock worth $581,000 after buying an additional 14 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares during the period. Wedbush Securities Inc. raised its stake in Intercept Pharmaceuticals by 1.8% in the second quarter. Wedbush Securities Inc. now owns 2,260 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 40 shares during the period. Sheaff Brock Investment Advisors LLC raised its stake in Intercept Pharmaceuticals by 1.2% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 4,350 shares of the biopharmaceutical company’s stock worth $621,000 after buying an additional 50 shares during the period. Finally, Legal & General Group Plc raised its stake in Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares during the period. 81.86% of the stock is currently owned by institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.